Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a report released on Friday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Down 3.7 %

Shares of ENZ opened at $0.68 on Friday. The stock has a 50-day simple moving average of $0.94 and a 200-day simple moving average of $1.06. Enzo Biochem has a 1 year low of $0.68 and a 1 year high of $1.44.

Enzo Biochem (NYSE:ENZ) last announced its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.

Enzo Biochem Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were paid a $0.10 dividend. This represents a $0.40 annualized dividend and a dividend yield of 58.81%. The ex-dividend date was Friday, November 15th.

Hedge Funds Weigh In On Enzo Biochem

Hedge funds have recently bought and sold shares of the stock. BBR Partners LLC purchased a new stake in shares of Enzo Biochem during the 3rd quarter worth about $112,000. Renaissance Technologies LLC grew its position in shares of Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after buying an additional 64,417 shares in the last quarter. XTX Topco Ltd increased its position in shares of Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after purchasing an additional 13,735 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after buying an additional 11,742 shares during the last quarter. Hedge funds and other institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.